Position in VRTX
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,489,459,806
+$265,913,861 QoQ
Shares Held
2,998,530
+9.4% QoQ
Ownership
1.18%
of shares outstanding
% of Portfolio
0.90%
of 13F equity value
Holder Rank
#18
of 1,735 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority
Sole 92%
Shared 0%
None 8%
Common Shares in VRTX Over Time
Shares Held
Position Value (USD)
Derivatives in VRTX
reported options exposure · as of Mar 31, 2021CallValue
$6,446,700
CallShares
30,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026JENNISON ASSOCIATES LLC holds $3,761,825,691 across 45 Biotechnology names. VRTX ranks #1 (39.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
This page
|
2,998,530 | $1,489,459,806 | |
| 2 | ARGX |
Argenx SE
|
226,200 | $209,861,574 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
4,481,964 | $158,616,705 | |
| 4 | PVLA |
Palvella Therapeutics, Inc.
|
960,619 | $146,801,794 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
1,151,681 | $141,173,056 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
2,358,587 | $129,722,285 | |
| 7 | IMVT |
Immunovant, Inc.
|
3,310,238 | $127,543,470 | |
| 8 | ARQT |
Arcutis Biotherapeutics, Inc.
|
4,219,058 | $110,623,700 |
All Filings in VRTX
Export CSV
27 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,489,459,806 | 2,998,530 | Shares | Defined | 2026-08-03 | |
| 2026-03-31 | $1,223,545,945 | 2,740,059 | Shares | Defined | 2026-05-06 | |
| 2025-12-31 | $1,473,211,906 | 3,249,541 | Shares | Defined | 2026-01-30 | |
| 2025-09-30 | $1,353,095,442 | 3,454,947 | Shares | Defined | 2025-10-30 | |
| 2025-06-30 | $2,738,650,025 | 6,151,505 | Shares | Defined | 2025-08-01 | |
| 2025-03-31 | $2,454,373,129 | 5,062,442 | Shares | Defined | 2025-05-05 | |
| 2024-12-31 | $1,738,762,757 | 4,317,762 | Shares | Defined | 2025-01-24 | |
| 2024-09-30 | $2,581,373,520 | 5,550,386 | Shares | Defined | 2024-11-08 | |
| 2024-06-30 | $2,202,670,894 | 4,699,332 | Shares | Defined | 2024-08-05 | |
| 2024-03-31 | $1,999,080,155 | 4,782,374 | Shares | Defined | 2024-05-02 | |
| 2023-12-31 | $1,605,145,650 | 3,944,913 | Shares | Defined | 2024-02-01 | |
| 2023-09-30 | $1,320,600,026 | 3,797,665 | Shares | Defined | 2023-10-31 | |
| 2023-06-30 | $1,339,243,124 | 3,805,641 | Shares | Defined | 2023-08-03 | |
| 2023-03-31 | $1,442,957,900 | 4,579,801 | Shares | Defined | 2023-04-26 | |
| 2022-12-31 | $1,477,265,641 | 5,115,540 | Shares | Defined | 2023-02-09 | |
| 2022-09-30 | $1,377,000,411 | 4,755,821 | Shares | Defined | 2022-11-01 | |
| 2022-06-30 | $499,491,935 | 1,772,568 | Shares | Defined | 2022-08-02 | |
| 2022-03-31 | $91,362,987 | 350,090 | Shares | Defined | 2022-05-11 | |
| 2021-12-31 | $172,032,224 | 783,389 | Shares | Defined | 2022-02-08 | |
| 2021-09-30 | $150,437,428 | 829,359 | Shares | Defined | 2021-11-09 | |
| 2021-06-30 | $159,656,279 | 791,828 | Shares | Defined | 2021-08-12 | |
| 2021-03-31 | $6,446,700 | 30,000 | Call | Defined | 2021-05-11 | |
| 2021-03-31 | $153,815,898 | 715,789 | Shares | Defined | 2021-05-11 | |
| 2020-12-31 | $886,122,324 | 3,749,354 | Shares | Defined | 2021-02-05 | |
| 2020-09-30 | $982,103,937 | 3,609,084 | Shares | Defined | 2020-11-04 | |
| 2020-06-30 | $1,282,729,218 | 4,418,481 | Shares | Defined | 2020-08-06 | |
| 2020-03-31 | $1,037,879,601 | 4,361,755 | Shares | Defined | 2020-05-06 | |
| No filing history on record for this holder in this stock. | ||||||